Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies (VNARs) directed against the SARS-CoV-2 spike protein.
June 10, 2021
· 2 min read